Nanoparticle size influences the magnitude and quality of mucosal immune responses after intranasal immunization

Armando Stano, Chiara Nembrini, Melody A. Swartz, Jeffrey A. Hubbell, Eleonora Simeoni

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Background: The development of nanoparticulate antigen-delivery systems is an important emerging area of vaccinology, being sought to amplify immune responses to recombinant antigens that are poorly immunogenic. Nanoparticle size may play an important role in influencing the activity of such particulate-based adjuvants. Methods: To explore how the size of nanoparticles that are in the range of many common viruses can modulate the magnitude and quality of mucosal immune responses, the model antigen ovalbumin (OVA) was conjugated to 30. nm or 200. nm polypropylene sulfide nanoparticles (NPs) and administered intranasally to C57BL/6 mice. Results: We show that by increasing the size of the NPs from 30 to 200nm, OVA was more effectively delivered into both MHC class I and MHC class II-presentation pathways. Intranasal immunization with the 200nm NPs increased the magnitude of CD4+ T cell responses in the lungs, as well as systemic and mucosal humoral responses. Most importantly, 200nm NPs increased the proportion of antigen-specific polyfunctional CD4+ T cells as compared to 30nm NPs. Conclusions: The 200nm NPs are a very interesting antigen nanocarrier for prophylactic vaccines against mucosal pathogens that require multifunctional CD4+ T cells for protection. These results contribute to our understanding of how the size of an antigen-conjugated nanoparticle modulates mucosal immune responses to a protein antigen and may be useful to engineer subunit vaccines able to elicit appropriate mucosal immune responses that correlate with protection.

Original languageEnglish
Pages (from-to)7541-7546
Number of pages6
JournalVaccine
Volume30
Issue number52
DOIs
StatePublished - Dec 14 2012
Externally publishedYes

Fingerprint

mucosal immunity
Mucosal Immunity
nanoparticles
Nanoparticles
Immunization
immunization
antigens
Antigens
T-lymphocytes
ovalbumin
Ovalbumin
T-Lymphocytes
recombinant antigens
Subunit Vaccines
Cytoprotection
Polypropylenes
subunit vaccines
Histocompatibility Antigens Class II
vaccine development
polypropylenes

Keywords

  • Antigen-delivery system
  • Immunoengineering
  • Mucosal vaccine
  • Nanoparticle
  • Particulate-based adjuvant
  • Polyfunctional T cell

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

Nanoparticle size influences the magnitude and quality of mucosal immune responses after intranasal immunization. / Stano, Armando; Nembrini, Chiara; Swartz, Melody A.; Hubbell, Jeffrey A.; Simeoni, Eleonora.

In: Vaccine, Vol. 30, No. 52, 14.12.2012, p. 7541-7546.

Research output: Contribution to journalArticle

Stano, Armando ; Nembrini, Chiara ; Swartz, Melody A. ; Hubbell, Jeffrey A. ; Simeoni, Eleonora. / Nanoparticle size influences the magnitude and quality of mucosal immune responses after intranasal immunization. In: Vaccine. 2012 ; Vol. 30, No. 52. pp. 7541-7546.
@article{9e89051efb5a4b68aeaed5bf5e1e032e,
title = "Nanoparticle size influences the magnitude and quality of mucosal immune responses after intranasal immunization",
abstract = "Background: The development of nanoparticulate antigen-delivery systems is an important emerging area of vaccinology, being sought to amplify immune responses to recombinant antigens that are poorly immunogenic. Nanoparticle size may play an important role in influencing the activity of such particulate-based adjuvants. Methods: To explore how the size of nanoparticles that are in the range of many common viruses can modulate the magnitude and quality of mucosal immune responses, the model antigen ovalbumin (OVA) was conjugated to 30. nm or 200. nm polypropylene sulfide nanoparticles (NPs) and administered intranasally to C57BL/6 mice. Results: We show that by increasing the size of the NPs from 30 to 200nm, OVA was more effectively delivered into both MHC class I and MHC class II-presentation pathways. Intranasal immunization with the 200nm NPs increased the magnitude of CD4+ T cell responses in the lungs, as well as systemic and mucosal humoral responses. Most importantly, 200nm NPs increased the proportion of antigen-specific polyfunctional CD4+ T cells as compared to 30nm NPs. Conclusions: The 200nm NPs are a very interesting antigen nanocarrier for prophylactic vaccines against mucosal pathogens that require multifunctional CD4+ T cells for protection. These results contribute to our understanding of how the size of an antigen-conjugated nanoparticle modulates mucosal immune responses to a protein antigen and may be useful to engineer subunit vaccines able to elicit appropriate mucosal immune responses that correlate with protection.",
keywords = "Antigen-delivery system, Immunoengineering, Mucosal vaccine, Nanoparticle, Particulate-based adjuvant, Polyfunctional T cell",
author = "Armando Stano and Chiara Nembrini and Swartz, {Melody A.} and Hubbell, {Jeffrey A.} and Eleonora Simeoni",
year = "2012",
month = "12",
day = "14",
doi = "10.1016/j.vaccine.2012.10.050",
language = "English",
volume = "30",
pages = "7541--7546",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "52",

}

TY - JOUR

T1 - Nanoparticle size influences the magnitude and quality of mucosal immune responses after intranasal immunization

AU - Stano, Armando

AU - Nembrini, Chiara

AU - Swartz, Melody A.

AU - Hubbell, Jeffrey A.

AU - Simeoni, Eleonora

PY - 2012/12/14

Y1 - 2012/12/14

N2 - Background: The development of nanoparticulate antigen-delivery systems is an important emerging area of vaccinology, being sought to amplify immune responses to recombinant antigens that are poorly immunogenic. Nanoparticle size may play an important role in influencing the activity of such particulate-based adjuvants. Methods: To explore how the size of nanoparticles that are in the range of many common viruses can modulate the magnitude and quality of mucosal immune responses, the model antigen ovalbumin (OVA) was conjugated to 30. nm or 200. nm polypropylene sulfide nanoparticles (NPs) and administered intranasally to C57BL/6 mice. Results: We show that by increasing the size of the NPs from 30 to 200nm, OVA was more effectively delivered into both MHC class I and MHC class II-presentation pathways. Intranasal immunization with the 200nm NPs increased the magnitude of CD4+ T cell responses in the lungs, as well as systemic and mucosal humoral responses. Most importantly, 200nm NPs increased the proportion of antigen-specific polyfunctional CD4+ T cells as compared to 30nm NPs. Conclusions: The 200nm NPs are a very interesting antigen nanocarrier for prophylactic vaccines against mucosal pathogens that require multifunctional CD4+ T cells for protection. These results contribute to our understanding of how the size of an antigen-conjugated nanoparticle modulates mucosal immune responses to a protein antigen and may be useful to engineer subunit vaccines able to elicit appropriate mucosal immune responses that correlate with protection.

AB - Background: The development of nanoparticulate antigen-delivery systems is an important emerging area of vaccinology, being sought to amplify immune responses to recombinant antigens that are poorly immunogenic. Nanoparticle size may play an important role in influencing the activity of such particulate-based adjuvants. Methods: To explore how the size of nanoparticles that are in the range of many common viruses can modulate the magnitude and quality of mucosal immune responses, the model antigen ovalbumin (OVA) was conjugated to 30. nm or 200. nm polypropylene sulfide nanoparticles (NPs) and administered intranasally to C57BL/6 mice. Results: We show that by increasing the size of the NPs from 30 to 200nm, OVA was more effectively delivered into both MHC class I and MHC class II-presentation pathways. Intranasal immunization with the 200nm NPs increased the magnitude of CD4+ T cell responses in the lungs, as well as systemic and mucosal humoral responses. Most importantly, 200nm NPs increased the proportion of antigen-specific polyfunctional CD4+ T cells as compared to 30nm NPs. Conclusions: The 200nm NPs are a very interesting antigen nanocarrier for prophylactic vaccines against mucosal pathogens that require multifunctional CD4+ T cells for protection. These results contribute to our understanding of how the size of an antigen-conjugated nanoparticle modulates mucosal immune responses to a protein antigen and may be useful to engineer subunit vaccines able to elicit appropriate mucosal immune responses that correlate with protection.

KW - Antigen-delivery system

KW - Immunoengineering

KW - Mucosal vaccine

KW - Nanoparticle

KW - Particulate-based adjuvant

KW - Polyfunctional T cell

UR - http://www.scopus.com/inward/record.url?scp=84870489032&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870489032&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2012.10.050

DO - 10.1016/j.vaccine.2012.10.050

M3 - Article

C2 - 23103199

AN - SCOPUS:84870489032

VL - 30

SP - 7541

EP - 7546

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 52

ER -